Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax held its Annual Meeting on June 20, 2025, with 95,359,194 shares represented out of 161,968,503 total outstanding shares. Three key proposals were voted upon:
1. Board Elections: Three Class III directors were elected for three-year terms:
- Rachel K. King (38.3M for, 19.1M against)
- John W. Shiver (43.7M for, 13.8M against)
- Charles W. Newton (42.8M for, 14.6M against)
2. Executive Compensation: Shareholders approved named executive officers' compensation in an advisory vote (41.3M for, 15.8M against)
3. Auditor Appointment: Ernst & Young LLP was ratified as independent auditor for FY2025 with strong approval (79.3M for, 15.1M against)